Glecaprevir/pibrentasvir - AbbVie
Alternative Names: 2DAA; ABT-493/ABT-530; GLE/PIB; Glecaprevir Hydrate/Pibrentasvir - AbbVie; HCV Next Gen; MAVIRET; MAVYRET; Pibrentasvir/glecaprevir; Pibrentasvir/glecaprevir-AbbvieLatest Information Update: 17 Jun 2025
At a glance
- Originator AbbVie; Enanta Pharmaceuticals
- Developer AbbVie
- Class Antivirals; Aza compounds; Benzimidazoles; Carbamates; Cyclic ethers; Cyclopentanes; Cyclopropanes; Fluorobenzenes; Piperidines; Pyrrolidines; Quinoxalines; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 11 Jun 2025 AbbVie launched glecaprevir/pibrentasvir for Hepatitis C (In adolescents, In adults, In children, In the elderly) in USA
- 11 Jun 2025 The US FDA approves glecaprevir/pibrentasvir for Hepatitis C (In adolescents, In adults, In children, In the elderly) in USA
- 15 Nov 2024 Adverse events and efficacy data from a phase-III trial in Hepatitis C presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)